IgAN is the most common type of glomerulonephritis worldwide, affecting an estimated 120,000 patients in the US1
Deposits of IgA complexes in the glomerular mesangium trigger an immune response that results in persistent inflammation, proteinuria, glomerular fibrosis, and ultimately a reduction of kidney function progressing to ESRD1,2
PHOENIX Trial Overview
PHOENIX is an open-label, multicenter, phase 2 US trial designed to evaluate the safety, tolerability, and efficacy of bardoxolone methyl in four separate patient cohorts. The target enrollment is 25 to 30 patients per cohort.
PHOENIX Trial Details
Patient cohorts: ADPKD, IgAN, T1D CKD, and FSGS
Age: 18-65 years
eGFR: 30-90 mL/min/1.73 m2
Primary endpoint: change from baseline in eGFR at week 12
Treatment: bardoxolone methyl, orally, once daily for 12 weeks
Penfold RS, Prendecki M, McAdoo S, Tam FW. Primary IgA nephropathy: Current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137-148.
National Institute of Diabetes and Digestive and Kidney Diseases. IgA nephropathy. www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy. Accessed November 8, 2018.